Skip to main content
Caplight Logo









Medisola

Medisola

Private
SeoulHealthcare & Life Scienceshttps://www.medisola.co.kr/

Last Round

Series A

Apr 3, 2025

Total Funding Raised

$11.1M

Company Overview

Medisola is a food-tech company that provides personalized nutritional solutions and meal plans based on medical data and AI for preventative health and disease management.

Sector

Healthcare & Life Sciences

Verticals

D2C Brands, Medical AI, Subscription Commerce

Business Model

B2C

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

personalized nutritionmedically tailored mealsfood as medicinechronic disease managementAI meal planningdigital health platformnutritional analysispreventive nutritionready-to-eat mealsfood-techemployee assistance programsEAPclinical nutritionsubscription meal service

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Medisola Comparables

Compare Medisola with similar companies based on industry and business-model similarity.

Medisola comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eatmaple
87%
Eatmapl
84%
SallyCook
82%

Medisola Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 3, 2025

Key People

Founding team and executive leadership

Young-Gil Yoon

경영지원실장(CFO) 상무

Executive Team

Junseung Lee

CPO

Executive Team

Medisola Investors

Notable investors and investment history

Medisola investors
InvestorRounds
Premier PartnersSeries A
Samsung Venture InvestmentSeries A
Redbadge PacificSeries A
Samsung Venture InvestmentSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Monthly visitors grew 105% MoM, reaching 33.7K.

  • Apr 7, 2025

    Developing ArchenX, an AI platform for diet planning and digital meal prescriptions.

Medisola Filings

Explore SEC and related filing metadata, where available.

Medisola filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Medisola's valuation, stock price, and market status.

Is Medisola a public or private company?

Medisola is a private company.

What is the current stock price of Medisola?

Medisola is a private company with no public stock price. No recent secondary market data is available.

How much is Medisola worth (valuation)?

Valuation information for Medisola is not publicly available.

Can I buy Medisola stock?

Medisola shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Medisola's last funding round?

Medisola's most recent funding round was Series A on April 3, 2025.

Who are the main investors in Medisola?

Key investors in Medisola include Premier Partners, Redbadge Pacific, Samsung Venture Investment.

Will Medisola IPO soon?

No public IPO plans have been announced for Medisola.

How can I track Medisola secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Medisola's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range8
Year Founded2021
Last FundingApr 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?